Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open Label, Active Controlled Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous Bisphosphonates

NCT00104650 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00104650
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00104650 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open Label, Active Controlled Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous Bisphosphonates
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2005
Completion date
March 31, 2010
Enrollment
111 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

bone metastases in men with hormone-refractory prostate cancer, bone metastases in subjects with advanced breast cancer, bone metastases in subjects with advanced cancer or multiple myeloma